What type of study is this?

This is a Literature Review study.

Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence

View Full Paper

Ask AI

Bookmark

Authors

Integrated review highlights clinical outcomes and patient-centered perspectives for myelodysplastic syndromes treatment.

Oral decitabine and cedazuridine improved treatment persistence in myelodysplastic syndromes, reducing patient burden.
The review incorporates clinical, economic, and patient-centered evidence to evaluate the value of oral DEC-C.
Patient-centered outcomes are crucial in assessing the therapeutic value of treatments for older individuals with MDS.
Suboptimal use of hypomethylating agents in MDS can lead to poorer outcomes and increased healthcare costs.

Zeidan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark